Matthew Jones

Matthew Jones
Occupation	Chief Technology Officer, Pharos
Known for	Co-founder of Pharos

Matthew Jones is a technology executive and entrepreneur who is the co-founder and Chief Technology Officer (CTO) of Pharos, a healthcare technology company that uses artificial intelligence to automate hospital quality reporting and help prevent avoidable patient harm. Pharos participated in Y Combinator's Summer 2024 batch and is based in San Francisco.

Career

Prior to founding Pharos, Jones worked at Vital.io, a health technology company that deployed AI models in hospital settings. He worked at Vital.io for nearly five years alongside his future co-founder, Felix Brann, who served as VP of Data Science at the company. During their time at Vital.io, Jones and Brann were involved in piloting the clinical adoption of a predictive sepsis model. Through this experience, they identified an opportunity to apply AI to empower hospital quality staff and improve patient outcomes, which led them to co-found Pharos in 2024.

At Pharos, Jones serves as CTO while Brann serves as CEO. The company addresses a significant operational challenge in healthcare: hospitals are required to submit data to state and national clinical quality registries, a process that traditionally requires clinicians to spend thousands of hours manually extracting complex facts from unstructured medical records. This manual abstraction is costly, diverts clinical staff from patient care, and results in data that is often only available long after patients have been discharged.

Pharos developed an AI-powered platform that automates the extraction of clinical data from unstructured medical records. The system enables hospitals to submit to quality registries without manual abstraction and allows quality teams to track custom process metrics in real time. By providing timely data, Pharos aims to help hospitals identify process failures contributing to patient harm, including issues such as sepsis mortality, hospital-acquired infections, and pressure ulcers.

In October 2024, Pharos announced the close of an oversubscribed $5 million seed round led by Felicis, with participation from General Catalyst, Moxxie, and Y Combinator. Moxxie had previously led the company's pre-seed round. The company stated it would use the funding to expand its engineering team and support reporting to additional clinical quality registries.